The Hesperos team recently gathered for a private screening of the upcoming feature documentary, The New Gold Standard: Cutting Edge Science That’s Replacing Animal Testing. As pioneers in human-on-a-chip technology, our routine focus centers on the … Read More
Join Hesperos at the 2026 MPS World Summit in Washington, DC If you are attending the MPS World Summit (Washington, DC, 26 – 29 May 2026), please stop by Booth 523 to learn more about how … Read More
A 4-organHuman-on-a-Chip® model was used to study the safety profile of tradipitant, the results supported its recent approval for motion sickness.
Featured on the cover of Advanced Science, our study presents a human-derived Malaria-on-a-Chip system that captures the biology of infection and delivers actionable insights for real-world therapeutic translation.
Hesperos and AsedaSciences announce a strategic channel sales partnership combining Human-on-a-Chip® and AI-driven 3RnD® to advance safer, more efficient drug and chemical development.
Hesperos and Oriental Yeast Co. form a strategic partnership to expand access to Human-on-a-Chip® services across Asia, accelerating safer, more effective preclinical drug development.
Hesperos and GalenusRx receive $3M NIH grant to study drug-induced dementia using Human-on-a-Chip® systems and improve medication safety for older adults.
PRESS RELEASE Key Results from Study First Digital Twin from Organ-on-a-Chip: Hesperos successfully created what’s believed to be the first digital twin derived from an organ-on-a-chip (microphysiological) system.Multi-Organ Human System: The study utilized a multi-organ system … Read More
Key Takeaways Hesperos aims to accelerate the preclinical development of Psilera’s lead compound, PSIL-006, targeting frontotemporal dementia (FTD). Press Release “Our platform offers a unique opportunity to assess the compound’s effects on neural tissues derived from … Read More
Highlights PharmaVoice interviewed Michael Shuler, President and Cofounder of Hesperos, and Lawrence Florin, CEO of Hesperos, along with other pharma leaders, about the future of New Approach Methodologies (NAMs) They discussed the recent pronouncements from … Read More